A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer.

@article{Gunawardana2003API,
  title={A phase I study of recombinant human leukemia inhibitory factor in patients with advanced cancer.},
  author={Dishan H. Gunawardana and Russell L. Basser and Ian D Davis and Jonathan Simon Cebon and Paul Mitchell and Craig Underhill and Trevor J. Kilpatrick and Katrina R Reardon and Michael Green and Peter Bardy and Pene Amor and David B Crump and Siobhan S Ng and Roger L. Nation and C. G. Begley},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2003},
  volume={9 6},
  pages={2056-65}
}
PURPOSE Leukemia inhibitory factor (LIF) is a pleiotropic molecule of the interleukin 6 family of cytokines. We aimed to examine the safety, pharmacokinetics, and biological effects of recombinant human LIF (rhLIF, emfilermin) in patients with advanced cancer. EXPERIMENTAL DESIGN In stage 1 of the study, 34 patients received rhLIF or placebo (3:1 ratio) at doses of 0.25-16.0 micro g/kg/day or 4.0 micro g/kg three times daily for 7 days. In stage 2, 40 patients received rhLIF or placebo… CONTINUE READING
10 Citations
32 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

A phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 Growth Factor) in women with breast cancer receiving chemotherapy

  • M. S. Gordon, J. Worta, +9 authors G. W. Sledge
  • 1996
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…